Overview

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Status:
Not yet recruiting

Trial end date:
2024-12-16

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Shanghai Pharmaceuticals Holding Co., Ltd